American University of Cardiology Announces Late-Breaking Clinical Trials

The American School of Cardiology announced the lineup of late-breaking clinical trials for its approaching yearly meeting in Washington, DC. The opening session will incorporate the most eagerly anticipated trials– the main outcomes of  Symplicity HTN-three and the  comparison of Corevalve and surgical procedure in substantial threat sufferers. Subsequent sessions will include many phase 3 trials of  PCSK9 inhibitors. Right here is the total record of trials:

ACC.14 Opening Showcase and the Joint ACC/JACC Late-Breaking Clinical Trials

• March 29, 2014, eight:00 – ten:00 AM


• Chair: John Gordon Harold


• Panelists: Valentin Fuster. David E. Kandzari. Sanjay Kaul. Michael J. Mack

9:ten – 9:25 AM 451-13 - A Randomized Comparison of Self-expanding Transcatheter and Surgical Aortic Valve Substitute in Individuals with Significant Aortic Stenosis Deemed Higher-Risk for Surgical procedure

• David H. Adams, Michael J. Reardon, Steven J. Yakubov, Joseph S. Coselli, G. Michael Deeb, Thomas G. Gleason, Maurice Buchbinder, Blase Carabello, James Hermiller, Jr., Patrick W. Serruys, Neal S. Kleiman, Stanley Chetcuti, John Heiser, William Merhi, George Zorn, Peter Tadros, Newell Robinson, George Petrossian, G. Chad Hughes, J. Kevin Harrison, John Conte, Jae K. Oh, Jeffrey J. Popma, Mount Sinai Healthcare Center, New York, NY, USA

9:35 – 9:50 AM 451-15 - The Principal Benefits of SYMPLICITY HTN-three

• Deepak L. Bhatt, David Kandzari, William O’Neill, Ralph D’Agostino, Murray Esler, John Flack, Barry Katzen, Martin Leon, Minglei Liu, Laura Mauri, Manuela Negoita, Suzanne Oparil, Krishna Rocha-Singh, Paul Sobotka, Raymond Townsend, George Bakris, for the SYMPLICITY HTN-3 Investigators, Brigham and Women’s Hospital Heart and Vascular Center, Boston, MA, USA, University of Chicago, Chicago, IL, USA

Joint American University of Cardiology/Journal of the American Medical Association Late-Breaking Clinical Trials

• March 30, 2014, eight:00 – 9:15 AM Hall D (Primary Tent)


• Co-Chairs: Howard C. Bauchner, Prediman K. Shah


• Panelists: Joseph S. Alpert, Roger S. Blumenthal, Jeffrey T. Kuvin, Roxana Mehran, Nathan D. Wong

8:00 – eight:10 AM 402-08 - Result of Inhibition of Lipoprotein-Linked Phospholipase A2 with Darapladib on Ischemic Events in Sufferers with Chronic Coronary Heart Condition: The STABILITY (STabilisation of Atherosclerotic plaque By Initiation of darapLadIb Therapy) Trial

• Harvey D. White, Claes Held, Ralph Stewart, Philippe Steg, Andrzej Budaj, Robert Harrington, Elizabeth Tarka, Rebekkah S. Brown, Christopher Cannon, Lars Wallentin, the STABILITY Investigators., Green Lane Cardiovascular Service, Auckland City Hospital, Auckland, New Zealand, Uppsala Clinical Analysis center, Uppsala, Sweden

8:15 – eight:25 AM 402-ten - The Low-density Lipoprotein Cholesterol Evaluation With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy – 2 Trial: A Phase 3, Double-blind, Randomized, Placebo and Ezetimibe Managed, Multicenter Review to Assess Security, Tolerability and Efficacy of Evolocumab (AMG 145) in Combination With Statin Treatment in Subjects With Primary Hypercholesterolemia and Mixed Dyslipidemia

• Jennifer Robinson, Bettina S. Nedergaard, William Rogers, Jonathan Fialkow, Joel Neutel, David Ramstad, Ransi Somaratne, Jason Legg, Patric Nelson, Robert Scott, Scott Wasserman, Robert Weiss, for the LAPLACE-2 Investigators, Amgen Inc., Thousand Oaks, CA, USA

8:30 – 8:40 AM 402-twelve - Evaluation of the Dual PPAR-αγ Agonist Aleglitazar to Minimize Cardiovascular Occasions in Individuals with Acute Coronary Syndrome and Sort 2 Diabetes Mellitus: the AleCardio Trial

• A. Michael Lincoff, Jean Claude Tardif, Bruce Neal, Stephen Nicholls, Lars Ryden, Gregory Schwartz, Klas Malmberg, John Buse, Robert Henry, Hans Wedel, Arlette Weichert, Anders Svensson, Ruth Cannata, Diederick Grobbee, AleCardio Examine Investigators, Cleveland Clinic, Cleveland, OH, USA

8:45 – eight:55 AM 402-14 - Two-yr End result of a Trial Comparing Second Generation Drug-eluting Stents Making use of Either Biodegradable Polymer or Resilient Polymer: the NOBORITM Biolimus-Eluting versus XIENCETM/PROMUSTM Everolimus-eluting Stent Trial (Up coming)

• Masahiro Natsuaki, Ken Kozuma, Takeshi Morimoto, Kazushige Kadota, Toshiya Muramatsu, Yoshihisa Nakagawa, Takashi Akasaka, Keiichi Igarashi, Kengo Tanabe, Yoshihiro Morino, Tetsuya Ishikawa, Hideo Nishikawa, Masaki Awata, Mitsuru Abe, Hisayuki Okada, Yoshiki Takatsu, Nobuhiko Ogata, Kazuo Kimura, Kazushi Urasawa, Yasuhiro Tarutani, Nobuo Shiode, Takeshi Kimura, Kyoto University, Kyoto, Japan, Saiseikai Fukuoka Common Hospital, Fukuoka, Japan

9:00 – 9:10 AM 402-sixteen - A Phase 3 Double-blind, Randomized Review to Assess the Security and Efficacy of Evolocumab (AMG 145) in Hypercholesterolemic Subjects Unable to Tolerate an Successful Dose of Statin

• Erik S.G. Stroes, David Colquhoun, David Sullivan, Fernando Civeira, Robert Rosenson, Gerald F. Watts, Eric Bruckert, Ricardo Dent, Allen Xue, Robert Scott, Scott Wasserman, Michael Rocco, GAUSS-two Investigators, Amgen Inc., Thousand Oaks, CA, USA

Late-Breaking Clinical Trials III

• March thirty, 2014, ten:45 – 12:00 PM Hall D (Principal Tent)


• Co-Chairs: Rick A. Nishimura, Evan M. Zahn


• Panelists: George L. Bakris, Massimo Imazio, Allan S. Jaffe, Michael Shehata, Ronald G. Victor

ten:45 – 10:fifty five AM 403-08 - Efficacy And Safety Of Colchicine In Patients With Several Recurrences Of Pericarditis: Final results Of A Multicenter, Double-blind, Placebo-managed, Randomized Research (corp-two Trial).

• Massimo Imazio, Riccardo Belli, Antonio Brucato, Roberto Cemin, Stefania Ferrua, Yehuda Adler, David H. Spodick, Rita Trinchero, Cardiology Division, Maria Vittoria Hospital, Torino, Italy

11:00 – eleven:10 AM 403-ten - The Worldwide SYMPLICITY Registry: Security and Effectiveness of Renal Artery Denervation In Actual Globe Individuals With Uncontrolled Hypertension

• Michael Bohm, Markus Schlaich, Krzysztof Narkiewicz, Luis Ruilope, Bryan Williams, Roland Schmieder, Felix Mahfoud, Giuseppe Mancia, Universitätskliniken des Saarlandes, Klinik für Innere Medizin III, Homburg/Saar, Germany

eleven:15 – 11:25 AM 403-12 - A single 12 months Adhere to-up of the Melody Transcatheter Pulmonary Valve Multicenter Publish Approval Review

• Aimee K. Armstrong, David Balzer, Allison Cabalka, Robert Gray, Alexander Javois, Jacqueline Kreutzer, John Moore, Jonathan Rome, Daniel Turner, Thomas Zellers, University of Michigan C.S. Mott Children’s Hospital, Ann Arbor, MI, USA, Children’s Hospital of Pittsburgh, Pittsburgh, PA, USA

eleven:thirty – eleven:40 AM 403-14 - Lengthy-term Survival with Cardiac Resynchronization Treatment in Individuals with Mild Heart Failure

• Ilan Goldenberg, Valentina Kutyifa, Helmut Klein, Scott McNitt, Scott Solomon, Arthur Moss, MADIT-CRT Executive Committee, University of Rochester Health-related Center, Rochester, NY, USA, Sheba Healthcare Center, Tel Hashomer, Israel

11:45 – eleven:55 AM 403-16 - Adverse High-Delicate Troponins in the Emergency Department and Risk of Myocardial Infarction

• Nadia Bandstein, Magnus Johansson, Rickard Ljung, Martin Holzmann, Karolinska Institutet, Stockholm, Sweden

Joint American University of Cardiology/New England Journal of Medicine Late-Breaking Clinical Trials

• March 31, 2014, eight:00 – 9:15 AM Hall D (Primary Tent)


• Co-Chairs: John A. Jarcho, Steven E. Nissen


• Panelists: Yochai Birnbaum, Scott Cunneen, Michael H. Davidson, D. Craig Miller, Freek W. A. Verheugt

eight:00 – eight:10 AM 404-08 - The Influence of Acetyl-Salicylic Acid on Main Arterial and Venous Problems in Patients Undergoing Noncardiac Surgery

• P.J. Devereaux, POISE-two Investigators, Population Health Research Institute, Hamilton, Canada

eight:15 – 8:25 AM 404-ten - A Big Global Trial Assessing the Results of Clonidine on Significant Arterial Events in Individuals Obtaining Noncardiac Surgical treatment

• Daniel I. Sessler, P.J. Devereaux, POISE-2 Investigators, Outcomes Research, Cleveland Clinic, Cleveland, OH, USA

8:30 – 8:40 AM 404-twelve - Steroids in Cardiac Surgical procedure Trial (SIRS)

• Richard Whitlock, Population Overall health Study Institute, McMaster University/Hamilton Overall health Sciences, Hamilton, Canada

eight:45 – 8:55 AM 404-14 - Metformin in Acute Myocardial Infarction

• Chris PH Lexis, Iwan CC van der Horst, Erik Lipsic, Jan Tijssen, Pim van der Harst, Dirk van Veldhuisen, GIPS-III Investigators, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands, Academic Health care Center, University of Amsterdam, Amsterdam, The Netherlands

9:00 – 9:ten AM 404-16 - Effect of Bariatric Surgical procedure vs. Intensive Medical Treatment on Extended-phrase Glycemic Manage and Complications of Diabetes: 3-Year STAMPEDE Trial Final results

• Philip Raymond Schauer, John Kirwan, Kathy Wolski, Stacy Brethauer, Sankar Navaneethan, Ali Aminian, Claire Pothier, Steven Nissen, Deepak Bhatt, Sangeeta Kashyap, Cleveland Clinic, Cleveland, OH, USA

Late-Breaking Clinical Trials V: TCT@ACC-i2

• March 31, 2014, 10:45 – twelve:00 PM Hall D (Major Tent)


• Co-Chairs: Cindy L. Grines, David E. Kandzari


• Panelists: David L. Brown, David E. Kandzari, Dean J. Kereiakes, Roxana Mehran, William W. O’Neill

10:45 – 10:55 AM 405-08 - One Year Outcomes from the STS/ACC Transcatheter Valve Therapy (TVT) Registry

• David R. Holmes, J. Matthew Brennan, John Rumsfeld, Dadi (David) Dai, Fred Edwards, John Carroll, David Shahian, Frederick Grover, E. Murat Tuzcu, Eric Peterson, Ralph Brindis, Michael Mack, Mayo Clinic, Rochester, MN, USA

11:00 – eleven:10 AM 405-10 - A Randomized Comparison of Self-Expandable and Balloon-Expandable Prostheses in Patients Undergoing Transfemoral Transcatheter Aortic Valve Substitute – The Choice Trial

• Mohamed Abdel-Wahab, Julinda Mehilli, Ulrich Schäfer, FJ Neumann, Thomas Kurz, Ralph Toelg, Bettina Schwarz, Ken Gordian, Volker Geist, Steffen Massberg, Christian Frerker, Mohamed El-Mawardy, Gert Richardt, Heart Center, Segeberger Kliniken, Bad Segeberg, Germany

11:15 – eleven:25 AM 405-12 - Unfractionated Heparin versus Bivalirudin in Main Percutaneous Coronary Intervention: A Exclusive Randomized Controlled Trial with Consecutive, Unselected Patient Enrollment (using Delayed Consent), Developed to Reflect True-Planet, Contemporary Practice

• Adeel Shahzad, Ian Kemp, Christine Mars, Rob Cooper, Claire Roome, Keith Wilson, Rod Stables, HEAT-PPCI investigators, Institute of Cardiovascular Medicine and Science, Liverpool Heart and Chest Hospital NHS Believe in, Liverpool, United Kingdom

11:thirty – eleven:40 AM 405-14 - Bare Metal vs. Zotarolimus-eluting stent in Uncertain Drug-eluting Stent Candidates: A Randomized Controlled Trial

• Marco Valgimigli, ZEUS investigators, , Thoraxcenter, Erasmus MC, Rotterdam, The Netherlands

eleven:45 – eleven:fifty five AM 405-16 - Autotransplantation of Bone Marrow Derived Mesenchymal Stromal Cells in Individuals with Extreme Ischemic Heart Failure: The MSC-HF Trial

• Anders Bruun Mathiasen, Abbas Qayyum, Erik Jørgensen, Steffen Helqvist, Anne Fischer-Nielsen, Klaus Kofoed, Mandana Haack-Sørensen, Annette Ekblond, Jens Kastrup, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark, Denmark

American University of Cardiology Announces Late-Breaking Clinical Trials